[{"id":"7f332a49-0412-4b6e-b20f-d150a3b6718b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04508647","created_at":"2021-01-18T21:36:39.057Z","updated_at":"2024-07-02T16:35:13.496Z","phase":"Phase 2","brief_title":"Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma","source_id_and_acronym":"NCT04508647","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 07/14/2022","primary_completion_date":" 07/14/2022","study_txt":" Completion: 07/14/2022","study_completion_date":" 07/14/2022","last_update_posted":"2024-03-21"},{"id":"a2a1d2f4-d5fe-44f6-9d4b-6fab3db22983","acronym":"","url":"https://clinicaltrials.gov/study/NCT04783415","created_at":"2021-03-05T13:54:58.401Z","updated_at":"2024-07-02T16:35:28.898Z","phase":"Phase 2","brief_title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT04783415","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy) • rituximab biosimilar"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 09/20/2025","study_completion_date":" 09/20/2025","last_update_posted":"2023-11-17"},{"id":"0b5d05fa-af58-471b-8f6c-aaa3c0faf618","acronym":"GENUINE","url":"https://clinicaltrials.gov/study/NCT02301156","created_at":"2021-01-17T18:01:38.285Z","updated_at":"2024-07-02T16:36:10.097Z","phase":"Phase 3","brief_title":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT02301156 - GENUINE","lead_sponsor":"TG Therapeutics, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Briumvi (ublituximab-xiiy)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 01/27/2015","start_date":" 01/27/2015","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2022-05-20"}]